1. Home
  2. SSII vs TBPH Comparison

SSII vs TBPH Comparison

Compare SSII & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSII

SS Innovations International Inc.

HOLD

Current Price

$3.98

Market Cap

1.1B

Sector

N/A

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$20.28

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSII
TBPH
Founded
N/A
2013
Country
India
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SSII
TBPH
Price
$3.98
$20.28
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$27.80
AVG Volume (30 Days)
112.0K
358.2K
Earning Date
03-20-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.58
Revenue
$36,066,457.00
$80,327,000.00
Revenue This Year
N/A
$70.78
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$35.29
Revenue Growth
158.36
27.12
52 Week Low
$3.02
$7.90
52 Week High
$22.42
$21.03

Technical Indicators

Market Signals
Indicator
SSII
TBPH
Relative Strength Index (RSI) 29.30 53.35
Support Level $3.40 $18.78
Resistance Level $6.01 $20.50
Average True Range (ATR) 0.52 0.78
MACD -0.15 -0.08
Stochastic Oscillator 11.46 44.00

Price Performance

Historical Comparison
SSII
TBPH

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: